Curi Bio Launches MantaReady™ iPSC-Derived Skeletal Muscle Myoblasts
Curi Bio , a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of their MantaReadyTM iPSC-Derived Skeletal Muscle Myoblasts specifically optimized for creating human 3D engineered muscle tissues for preclinical therapeutic discovery, high-throughput screening, and disease modeling.
- Curi Bio , a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of their MantaReadyTM iPSC-Derived Skeletal Muscle Myoblasts specifically optimized for creating human 3D engineered muscle tissues for preclinical therapeutic discovery, high-throughput screening, and disease modeling.
- View the full release here: https://www.businesswire.com/news/home/20230606005566/en/
Curi Bio Launches MantaReady™ 3D Skeletal Muscle Myoblasts – Ready to Cast Isogenic Control and Duchenne Muscular Dystrophy Human Myoblasts for 3D Engineered Muscle Tissue (Photo: Business Wire)
The myoblast lines were developed in response to the growing demand for high quality iPSC-derived cells required for 3D skeletal muscle engineering. - “Through our innovative technology, we’re able to provide researchers with high-quality skeletal muscle cells that can be used to accelerate the drug discovery process and translational muscle biology research,“ said Curi Bio CEO Nick Geisse.
- To learn more about how MantaReady iPSC-derived skeletal muscle cells can improve the predictive power of your experiments, or about Curi Bio’s other human-relevant preclinical platform technologies and services, please reach out at www.curibio.com/contact .